NEWS

Recent News about GEG Tech

  • Universal CAR T cell therapy helps beat a hard-to-treat pediatric cancer

    Acute lymphoblastic leukemia (ALL) accounts for 25% of all pediatric cancer cases in the United States. There are several options for treating ALL in children aged 1-10 years, but infants under one year of age generally have a much poorer...Read More »
  • Modified version of CAR T-cell therapy shows promise in targeting neuroblastoma

    The development of CAR T cells has facilitated the treatment of blood tumors. Moreover, this therapy is not effective against solid tumors such as neuroblastoma and has even revealed toxic effects that are due to the fact that most of...Read More »
  • Penn study opens the door to let CAR T cells reach the tumor microenvironment

    The network of blood vessels in the tumour microenvironment remains one of the most difficult blockages for cell therapies to penetrate and treat solid tumours. However, a new study published in Nature Cancer explains that researchers at Penn Medicine found that combining CAR T cell therapy with a PAK4 inhibitor drug allowed modified cells to work their way through and attack the tumour, leading to significantly improved survival in mice. The genetic reprogramming of tumour endothelial cells lining the walls of blood vessels is caused by an enzyme known as PAK4. Penn’s team discovered that this enzyme reduces abnormal tumour vascularisation and improves T cell infiltration and CAR T cell immunotherapies in mouse models of glioblastoma. An experiment with T-RCA cell therapy led by EGFRvIII and a PAK4 inhibitor showed a nearly 80 percent reduction in tumour growth compared to mice that received CAR T cell therapy only five days after infusion. The targeting of PAK4 may therefore provide a unique opportunity to recondition the tumour microenvironment and improve T-cell–based cancer immunotherapy for solid tumours. Read More »
  • GEG-tech signs Distribution Agreement with tebu-bio

    GEG-tech signs Distribution Agreement with tebu-bio

    GEG-tech signs Distribution Agreement with tebu-bio GEG-tech’s agreement with tebu-bio expands the distribution of advanced vectorisation systems & tools, designed by GEG-tech (genetic engineering lab) into the European Market. GEG-tech, the technology leader in advanced lentiviral vectorisation systems, announces a...Read More »
  • Innovation in cancerology: meeting in Monaco

    Innovation in cancerology: meeting in Monaco

    Innovation in cancerology: meeting in Monaco GEG Tech will be attending the 14th Biennale Monegasque de Cancerologie. It will take place at the end on Januray 2020 in Monaco. More than 1300 participants will be gathering and discussing the evolution...Read More »

SCOOP-IT

Find all the latest topics curated by GEG Tech on Scoop It!.